Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study [PDF]
Frontiers in MedicineUtilization of novel Bruton tyrosine kinase inhibitors (BTKi) has become common for treating CLL/SLL patients, yet limited evidence exists on the clinical characteristics and outcomes following BTKi therapy discontinuation in China.
Yuting Yan +21 more
doaj +2 more sources
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Bruton tyrosine kinase (BTK) inhibitors (BTKi) have been proposed as therapy for thrombosis driven by immune complex activation of platelets via FcγRIIa.
Thomas Kartika +4 more
doaj +2 more sources
EJHaem, 2023 Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID‐19 infection and have poor immune responses to COVID‐19 vaccination. This study assessed whether a closely monitored pause in Bruton's Tyrosine Kinase inhibitor (BTKi)
Andrew Warden, Katherine Rankin
exaly +2 more sources
Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center
Advances in HematologyPatients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton’s tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited.
Mei Sheng Duh +2 more
exaly +2 more sources
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance [PDF]
Nature CommunicationsResistance to Bruton’s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies. Here, we identify chromatin remodeler BRG1-mediated suppression of ferroptosis as a central mechanism of BTKi resistance in mantle cell
Soo-Yeon Hwang +19 more
doaj +2 more sources
EJHaem, 2022 Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. Management strategies have evolved with the introduction of targeted therapy including new classes of Bruton tyrosine kinase inhibitor (BTKi ...
Rajeev Gupta, Jahanzaib Khwaja
exaly +2 more sources
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group [PDF]
Annals of HematologyIn relapsed/refractory (RR) chronic lymphocytic leukaemia (CLL), Bruton tyrosine kinase inhibitors (BTKi) are administered as monotherapy until disease progression.
Jana Mihályová +16 more
doaj +2 more sources
Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia [PDF]
Hematology ReportsBackground: Treatment options after Bruton’s tyrosine kinase inhibitors (BTKi) failure in Waldenstrom macroglobulinaemia are limited. Methods: We retrospectively analysed the use of bortezomib after BTKi failure in 17 patients who were heavily pre ...
Jahanzaib Khwaja +5 more
doaj +2 more sources
Frontiers in OncologyDermatological adverse events (AEs) are generally mild during therapy with Bruton’s tyrosine kinase inhibitor (BTKi), and it is often unnecessary to adjust the BTKi dosage or discontinue treatment.
Huayuan Zhu
exaly +3 more sources
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy [PDF]
Blood Cancer JournalAddition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials.
Yucai Wang +55 more
doaj +2 more sources